Strategies and Prospects for Vaccination Against the Hepatitis C Viruses

  • M. Houghton
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 242)

Abstract

In the USA, it has been shown that much of the hepatitis C virus (HCV)-associated disease burden arose from transmission through recreational drug use in which contaminated needles or syringes (or possibly cocaine straws; CONRY-CANTILENA et al. 1996) are shared (ALTER 1993). Currently, roughly 30,000 newly acquired acute HCV infections occur annually in the USA, most of which have intravenous drug use as the risk factor (ALTER 1993). However, in the remaining cases, multiple sexual partners remains an identified risk factor as does any activity subjecting the individual to exposure to contaminated blood (e.g. health-care workers, dialysis patients, organ recipients etc.; ALTER 1993). Therefore, while a prophylactic HCV vaccine would probably be used in high-risk groups initially, there would be a case for implementing universal vaccination of children (as in the case for the HBV vaccine) in order to prevent infection associated with adult activities. While there are similarities in the epidemiology of HCV between the USA and other developed countries, it appears that many developing countries suffer from a huge incidence of HCV infection due to past use of nondisposable injection needles/syringes in medical practices as well as cultural practices involving blood transfer. In these situations, public health measures and education programs are of paramount importance.

Keywords

Hepatitis Influenza Syringe Cocaine Interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams G, Kuntz S, Rabalais G, Bratcher D, Tamburro CH et al. (1997) Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children. Pediatr Infect Dis J 16:533–534PubMedCrossRefGoogle Scholar
  2. Allander T, Beyene A, Jacobson SH, Grillner L, Persson MAA (1997) Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response. J Infect Dis 175:26–31PubMedCrossRefGoogle Scholar
  3. Alter HJ (1989) Chronic consequences of non-A, non-B hepatitis. In: Seef LB, Lewis JH (eds) Current prospective in hepatology. Plenum, New York, pp 83–97Google Scholar
  4. Alter M J (1993) The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 2:155–166PubMedGoogle Scholar
  5. Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A et al. (1995) Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69:2462–2470PubMedGoogle Scholar
  6. Baumert TF, Ito S, Wong DT, Liang TJ (1998) Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72:3827–3836PubMedGoogle Scholar
  7. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331:1607–1611PubMedCrossRefGoogle Scholar
  8. Botarelli P, Brunetto MR, Minutello MA et al. (1993) T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 104:580–587PubMedGoogle Scholar
  9. Boyle JS, Brady JL, Lew AM (1998) Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392:408–411PubMedCrossRefGoogle Scholar
  10. Bruna-Romero O, Lasarte J J, Wilkinson G, Grace K, Clarke B et al. (1997) Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25:470–477PubMedCrossRefGoogle Scholar
  11. Bukh J, Emerson SU, Purcell RH (1997) Genetic heterogeneity of hepatitis C virus and related viruses. In: Rizzetto M, Purcell RH, Gerin JL, Verme G (eds) Viral hepatitis and liver disease. Edizioni Minerva Medica, Torino, pp 167–175Google Scholar
  12. Bukh J, Purcell RH, Miller RH (1993) At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Natl Acad Sci USA 90:8234–8238PubMedCrossRefGoogle Scholar
  13. Bukh J, Purcell RH, Miller RH (1994) Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 91:8239–8243PubMedCrossRefGoogle Scholar
  14. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA et al. (1995) Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95:521–530PubMedCrossRefGoogle Scholar
  15. Chen C-M, You L-R, Hwang L-H, Wu Lee Y-H (1997) Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-ß receptor modulates the signal pathway of the lymphotoxin-ß receptor. J Virol 71:9417–9426PubMedGoogle Scholar
  16. Chien DY, Choo Q-L, Ralston R, Spaete R et al. (1993) Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet 342:933PubMedCrossRefGoogle Scholar
  17. Choo Q-L, Kuo G, Ralston R et al. (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91:1294–1298PubMedCrossRefGoogle Scholar
  18. Choo Q-L, Richman KH, Han JH et al. (1991) Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 88:2451–2455PubMedCrossRefGoogle Scholar
  19. Christie JML, Healey CJ, Watson J, Wong VS, et al. (1997) Clinical outcome of hypo- gammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow-up. Clin Exp Immunol 110:4–8PubMedCrossRefGoogle Scholar
  20. Conry-Cantilena C, Vanraden M, Gibble J, Melpoler J, Shakil AO et al. (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334:1691–1696PubMedCrossRefGoogle Scholar
  21. Cooper S, Erickson AL, Adams EJ, Kansspan J, Weiner AJ et al. (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10:439–449PubMedCrossRefGoogle Scholar
  22. Deleersnyder V, Pillez A, Wychowski C, Blight K, Xu J et al. (1997) Formation of native hepatitis C virus glycoprotein complexes. J Virol 71:697–704PubMedGoogle Scholar
  23. Diepolder HM, Gerlach J-T, Zachoval R, Hoffman RM, Jung M-C et al. (1997) Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71:6011–6019PubMedGoogle Scholar
  24. Diepolder HM, Zachoval R, Hoffman RM, Wierenga EA, Santantonio T et al. (1995) Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006–1007PubMedCrossRefGoogle Scholar
  25. Donelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW et al. (1995) Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1:583–587CrossRefGoogle Scholar
  26. Driver DA, Polo JM, Belli BA, Banks TA, Mangala H, Dubensky TW Jr (1998) Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization. Mol Ther 1:510–520Google Scholar
  27. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM (1994) Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68:6147–6160PubMedGoogle Scholar
  28. Farci P, Alter HJ, Govindarajan S et al. (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140PubMedCrossRefGoogle Scholar
  29. Farci P, Shimoda A, Wong D, Cabezón T, De Gioannis D et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93:15394–15399PubMedCrossRefGoogle Scholar
  30. Féray C, Gigai M, Samuel D, Ducot B, Maissonneuve P et al. (1998) Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128:810–816PubMedGoogle Scholar
  31. Geissler M, Gesien A, Tokushige K, Wands JR (1997) Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine- expressing plasmids. J Immunol 158:1231–1237PubMedGoogle Scholar
  32. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 88:5547–5551PubMedCrossRefGoogle Scholar
  33. Houghton M, Choo Q-L, Chien D, Kuo G, Weiner A et al. (1997) Development of an HCV vaccine. In: Rizzetto M, Purcell RH, Gerin JL, Verme G (eds) Viral hepatitis and liver disease. Edizioni Minerva Medica, Torino, pp 656–659Google Scholar
  34. Inchauspé G, Major ME, Nakano I, Vitvitski L, Trépo C (1997) DNA vaccination for the induction of immune responses against hepatitis C virus proteins. Vaccine 15:853–856PubMedCrossRefGoogle Scholar
  35. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H et al. (1998) High titers of envelope neutralizing antibodies correlate with natural resolution of chronic hepatitis C. Hepatology (in press). Google Scholar
  36. Kato N, Ootsuyama Y, Sekiya H et al. (1994) Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol 68:4776–4784PubMedGoogle Scholar
  37. Kikughi K, Tateda A (1980) A trial for prevention of serum hepatitis with intravenous human gammaglobulin (venoglobulin). J Jpn Soc Blood Transfus 24:2–8Google Scholar
  38. Kita H, Moriyama T, Kaneko T et al. (1993) HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 18:1039–1044PubMedGoogle Scholar
  39. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ (1976) Efficacy of prophylactic gamma-globulin in preventing non-A, non-B posttransfusion hepatitis. Lancet 1:557–561PubMedCrossRefGoogle Scholar
  40. Knodell RG, Conrad NE, Ishak KG (1977) Development of chronic liver disease after acute non-A, non- B post-transfusion hepatitis: role of gamma globulin prophylaxis in its prevention. Gastroenterology 72:902–909PubMedGoogle Scholar
  41. Kobayashi M, Tanaka E, Matsumoto A, Ichijo T, Kiyosawa K (1997) Antibody response to E2/NS1 hepatitis C virus protein in patients with acute hepatitis C. J Gastroenterol Hepatol 12:73–76PubMedCrossRefGoogle Scholar
  42. Krawczynski K, Alter M J, Tankersley DL et al. (1993) Studies on protective efficacy of hepatitis C immunoglobulins (HCIG) in experimental hepatitis C virus infection. Hepatology 18:110CrossRefGoogle Scholar
  43. Lagging LM, Meyer K, Hoft D, Houghton M, Belshe RB, Ray R (1995) Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 69:5859–5863PubMedGoogle Scholar
  44. Lai ME, Mazzoleni AP, Argiolu F, Virgilis SD, Balesterieri A et al. (1994) Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343:388–390PubMedCrossRefGoogle Scholar
  45. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G et al. (1996) T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti- hepatitis C virus-positive blood donors without viremia. Hepatology 24:790–795PubMedGoogle Scholar
  46. Lechner S, Rispeter K, Meisel H, Kraas W, Jung G et al. (1998) Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Virology 243:313–321PubMedCrossRefGoogle Scholar
  47. Manickan E, Rouse RJ, Yu Z, Wire WS, Rouse BT (1995) Genetic immunization against herpes simplex virus: Protection is mediated by CD4+ T lymphocytes. J Immunol 155:259–265PubMedGoogle Scholar
  48. Martell M, Esteban JI, Quer J et al. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66:3225–3229PubMedGoogle Scholar
  49. Martins LP, Lau LL, Asano MS, Ahmed R (1995) DNA vaccination against persistent viral infection. J Virol 69:2574–2582PubMedGoogle Scholar
  50. Matsumoto M, Hsieh T-Y, Zhu N, vanArsdale T, Hwang AB et al. (1997) Hepatitis C virus interacts with the cytoplasmic tail of lymphotoxin-ß receptor. J Virol 71:1301–1309PubMedGoogle Scholar
  51. Michalak J-P, Wychowski C, Choukhi A, Meunier J-C, Ung S et al. (1997) Characterization of truncated forms of hepatitis C virus glycoproteins. J Gen Virol 78:2299–2306PubMedGoogle Scholar
  52. Minutello MA, Pileri P, Unutmaz et al. (1993) Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 178:17–25PubMedCrossRefGoogle Scholar
  53. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M et al. (1996) Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98:706–714PubMedCrossRefGoogle Scholar
  54. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K et al. (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78:1527–1531PubMedGoogle Scholar
  55. Nakano I, Maertens G, Major ME, Vitvitski L, Dubuisson J et al. (1997) Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 71:7101–7109PubMedGoogle Scholar
  56. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J et al. (1997) The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158:1473–1481PubMedGoogle Scholar
  57. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JYN (1998) Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28:225–230PubMedCrossRefGoogle Scholar
  58. Ogata N, Alter HJ, Miller RH, Purcell RH (1991) Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 88:3392–3396PubMedCrossRefGoogle Scholar
  59. Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA et al. (1997) Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. Arch Intern Med.157:1537–1544. PubMedCrossRefGoogle Scholar
  60. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M et al. (1992) Immunity in hepatitis C infection. J Infect Dis 165:438–443PubMedCrossRefGoogle Scholar
  61. Ralston R, Thudium K, Berger K et al. (1993) Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol 67:6753–6761PubMedGoogle Scholar
  62. Ray RB, Lagging LM, Meyer K, Steele R, Ray R (1995) Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 37:209–220PubMedCrossRefGoogle Scholar
  63. Ray RB, Lagging LM, Meyer K, Ray R (1996a) Hepatitis C virus core protein cooperates with ras and transform primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 70:4438–4443PubMedGoogle Scholar
  64. Ray RB, Meyer K, Ray R (1996b) Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226:176–182PubMedCrossRefGoogle Scholar
  65. Ray RB, Steele R, Meyer K, Ray R (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 272:10983–10986PubMedCrossRefGoogle Scholar
  66. Rehermann B, Chang K-M, McHutchison J, Kokka R, Houghton M et al. (1996a) Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70:7092–7102PubMedGoogle Scholar
  67. Rehermann B, Chang K-M, McHutchison JG, Kokka R, Houghton M, Chisari FV (1996b) Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 98:1432–1440PubMedCrossRefGoogle Scholar
  68. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L et al. (1996) A quantitative test to estimate neutralising antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 93:1759–1763PubMedCrossRefGoogle Scholar
  69. Ruggieri A, Harada T, Matsuura Y, Miyamura T (1997) Sensitization to fas-mediated apoptosis by hepatitis C virus core protein. Virology 229:68–76PubMedCrossRefGoogle Scholar
  70. Sakamuro D, Furukawa T, Takegami T (1995) Hepatitis C virus nonstructural protein NS3 transforms NIH3T3 cells. J Virol 69:3893–3896PubMedGoogle Scholar
  71. Sanchez-Quijano A, Lisen E, Diaz-Torres MA, Rivera F, Pineda JA et al. (1988) Prevention of posttransfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1:1245–1249PubMedCrossRefGoogle Scholar
  72. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH et al. (1994) Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 68:1494–1500PubMedGoogle Scholar
  73. Simmonds P, Mellor J, Nuchprayoon C, Tanprasert S, Smith DB (1997) Molecular epidemiology and classification of variants of hepatitis C virus found in South East Asia. In: Rizzetto M, Purcell RH, Gerin JL, Verme G (eds) Viral hepatitis and liver disease. Edizioni Minerva Medica, Torino, pp 187–194Google Scholar
  74. Spaete RR, Alexander D, Rugroden ME et al. (1992) Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology 188:819–830PubMedCrossRefGoogle Scholar
  75. Tang D, DeVit M, Johnston SA (1992) Genetic immunization is a simple method for eliciting an immune response. Nature 356:152–154PubMedCrossRefGoogle Scholar
  76. Thomssen R, Bonk S, Propfe C, Heermann K-H, Kochel HG et al. (1992) Association of hepatitis C virus in human sera with ß-lipoprotein. Med Microbiol Immunol 181:293–300PubMedCrossRefGoogle Scholar
  77. Tokushige K, Wakita T, Pachuk C, Moradpour D, Weiner DB et al. (1996) Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 24:14–20PubMedCrossRefGoogle Scholar
  78. Tsai S-L, Liaw Y-F, Chen M-H, Huang C-Y, Kuo GC (1997) Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449–458PubMedCrossRefGoogle Scholar
  79. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749PubMedCrossRefGoogle Scholar
  80. Wang B, Merva M, Dang K, Ugen KE, Boyer J et al. (1994) DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells. AIDS Res Hum Retroviruses 4:S35Google Scholar
  81. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E et al. (1995) Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 92:2755PubMedCrossRefGoogle Scholar
  82. Weiner AJ, Geysen HM, Christopherson C et al. (1992) Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 89:3468–3472PubMedCrossRefGoogle Scholar
  83. Williams WV, Boyer JD, Merva M, Livolsi V, Wilson B et al. (1993) Genetic infection induces protective in vivo immune responses. DNA Cell Biol 12:675–683PubMedCrossRefGoogle Scholar
  84. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  85. Wong DKH, Dudley DD, Afdhal NH, Dienstag J, Rice CM et al. (1998) Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 160:1479–1488PubMedGoogle Scholar
  86. Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Erti HC (1994) Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199:132–140PubMedCrossRefGoogle Scholar
  87. Yokoyama M, Zhang J, Whitton JL (1995) DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol 69:2684–2688PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • M. Houghton
    • 1
  1. 1.Chiron CorporationEmeryvilleUSA

Personalised recommendations